Breaking News

FDA Completes Inspection of Apicore Site in India

October 6, 2011

Vadodara site can now provide API manufacturing

Apicore LLC has completed its first inspection by the FDA of its subsidiary Apicore Pharmaceuticals Pvt Ltd., in Vadodara, Gujarat, India. The successful inspection allows the company to provide its customers with APIs manufactured in FDA inspected plants located in both the U.S. and India.  

To date, customers have obtained approval to market three generic drug products using APIs manufactured by Apicore. An additional 11 ANDAs have been filed referencing Drug Master Files (DMF) for APIs manufactured by the company.

Mr. Ambrose Stafford, vice president, sales and marketing said, "I feel great pride working with customers and the Apicore team to bring generic pharmaceutical products to market. Partnering with our customers, we're creating access to affordable drugs for patients and a return on investment for our customers and investors. The successful outcome of the FDA's first inspection of our plant in Vadodara, the fifth inspection of our plants in total, is an illustration of our organization's commitment to quality in everything that we do."

Related Contract Manufacturing:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks